Kent Ray, DO
Endocrinology, Diabetes & Metabolism · Eau Claire, WINPI 1598754350
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Dexcom, Inc. accounts for 60.5% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $567, more than ten times the $28 reported in 2019.
Across 93 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$1K
- Companion Medical, Inc.$237
- Novo Nordisk$125
- Medtronic$115
- Lilly USA, LLC$103
- Cequr Corporation$96
- plus $121 from 6 others
What the payments were for
- Food & beverage$2,017100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 66 | $1,220 |
| Companion Medical, Inc. | 3 | $237 |
| Novo Nordisk | 5 | $125 |
| Medtronic(2 entities) | 6 | $115 |
| Lilly USA, LLC | 5 | $103 |
| Cequr Corporation | 1 | $96 |
| Amgen(2 entities) | 2 | $38 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Bayer | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Abbott | 1 | $14 |
| Senseonics, Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InPen$224
How this compares
$2,017 in reported general payments places this provider in the 75th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $321,869 |
| TrulicityDulaglutide | 220 | $239,993 |
| ForteoTeriparatide | 46 | $199,922 |
| MounjaroTirzepatide | 163 | $171,537 |
| JardianceEmpagliflozin | 161 | $156,231 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 158 | $92,689 |
| Novolog FlexpenInsulin Aspart | 271 | $86,130 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $69,953 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 67 | $69,311 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $66,900 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $62,953 |
| Humalog Kwikpen U-100Insulin Lispro | 102 | $46,514 |
| JanuviaSitagliptin Phosphate | 28 | $40,759 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 233 | $40,010 |
| FarxigaDapagliflozin Propanediol | 41 | $37,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog | $103 | $615,158440 claims |
| Novo NordiskOzempic, Novolog | $125 | $342,959370 claims |
| AstraZenecaFarxiga | $17 | $37,02741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Eau Claire
- Aron AdkinsEau Claire$349K
- Marita FisherEau Claire$2K
- Odette MorganEau Claire$466
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.